DUSP8作为一种调节器,可以调节质母细胞瘤干细胞对瘤血管化的贡献
Giorgia Castellani1, Mariachiara Buccarelli1, Quintino Giorgio D'Alessandris2,3
1Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Journal of experimental & clinical cancer research : CR
|October 1, 2025
概括
质母细胞干细胞分化为血管细胞,推动瘤生长. 针对DUSP8,一个关键的调节器,提供了一个新的策略来抑制质母细胞瘤 (GBM) 血管化,并改善患者的生存率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质母细胞瘤 (GBM) 是一种具有侵略性的脑瘤,其特征是广泛的血管化.
- 质母细胞类干细胞 (GSCs) 可以转化为内皮细胞 (GdECs),有助于瘤血管生成.
- 了解控制 GSC 转分化的分子途径对于开发抗血管性疗法至关重要.
研究的目的:
- 为了确定分子机制和信号通路,调节GSC驱动的瘤血管化在GBM.
- 研究DUSP8和miR-1825在GSC转差和GBM血管生成中的作用.
- 探索调节DUSP8用于GBM治疗的治疗潜力.
主要方法:
- 识别一个三微RNA的签名区分GSCs从GdECs.
- 分析DUSP8作为被识别的miRNA签名调节的共同目标.
- 在体外和体内实验中评估DUSP8调制对GSC转差,血管生成和质生成的影响.
- 对DUSP8和miR-1825表达的相关性分析与GBM患者的临床数据.
主要成果:
- 确定了三个miRNA签名,其中miR-1825负调节DUSP8.8.
- DUSP8下调与增加的微血管密度和较差的生存时间有关,在GBM患者.
- DUSP8调制显著影响了GSC转分,MAPK通路活性和内皮细胞管的形成.
- 强制表达和静止DUSP8都影响了体内质生成.
结论:
- DUSP8是GSC转差和GBM血管生成的关键调节者.
- 在GBM患者中,DUSP8和miR-1825之间的反相关性突显了它们的临床相关性.
- 调节DUSP8为开发用于质母细胞瘤的新型抗血管生成疗法提供了一个有前途的治疗策略.
关键词:
在DUSP8P中,我们可以使用DUSP.内皮转基因差异化是内皮转基因差异化质母细胞瘤 (glioblastoma) 是一个质母细胞瘤 类似干细胞的细胞这就是MAPKs.在 MiR-182525 里面.更多相关视频
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
8.7K
10:08Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions
Published on: February 24, 2021
6.7K
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
